zen003694
Small moleculeexperimental
Clinical trial activity
8 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2016 (NCT02705469)
Timeline
Indications
Mechanism of action
- Bromodomain testis-specific proteinINHIBITOR
BRDT inhibitor
- Bromodomain-containing protein 2INHIBITOR
BRD2 inhibitor
- Bromodomain-containing protein 3INHIBITOR
BRD3 inhibitor
- BRD4/HDAC1INHIBITOR
BRD4/HDAC1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- zen003694
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06161493 | Phase 1 | Dec 31, 2023 | GlaxoSmithKline, University of Pittsburgh, Zenith Epigenetics |
| NCT05607108 | Phase 2 | Nov 1, 2022 | Memorial Sloan-Kettering Cancer Center, Zenith Epigenetics |
| NCT05071937 | Phase 2 | Jan 31, 2022 | Case Western Reserve University, Pfizer, University of Pittsburgh, Zenith Epigenetics |
| NCT04986423 | Phase 2 | Sep 8, 2021 | Astellas, Newsoara Biopharma Co., Ltd., Zenith Epigenetics |
| NCT04145375 | Phase 1/Phase 2 (Phase 2) | Nov 11, 2019 | Zenith Epigenetics |
| NCT03901469 | Phase 2 | Apr 30, 2019 | Pfizer, Zenith Epigenetics |
| NCT02711956 | Phase 1 | Dec 1, 2016 | Zenith Epigenetics |
| NCT02705469 | Phase 1 | Apr 1, 2016 | Zenith Epigenetics |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Zenith Epigenetics | For profit | 8 | 5 | 2 | 2016 |
| Pfizer | For profit | 2 | 0 | 1 | 2019 |
| University of Pittsburgh | Academic/Hospital | 2 | 1 | 2 | 2022 |
| Astellas | For profit | 1 | 0 | 1 | 2021 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2023 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Newsoara Biopharma Co., Ltd. | For profit | 1 | 0 | 1 | 2021 |
8 organizations
Page 1 / 1